News
AOP Orphan hosted an Experts Press Conference at DGHO in Berlin
7. 10. 2019AOP Orphan hosted Industry Symposium at DGHO in Berlin
7. 10. 2019AOP Orphan Pharmaceuticals AG, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
13. 5. 2019
From the Concept to the Drug
AOP Orphan headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Orphan headquarters using the link below.